We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
- Recent JNJ Stock Price: $151.24
- Yearly Gain for JNJ stock: -3.59%
- Market Cap for JNJ stock: $363.99B
- P/E Ratio for JNJ stock: 22.47
Will JNJ's stock price go up? Is there an accurate JNJ stock forecast available?
TipRanks.com reports that Johnson & Johnson currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $179.50. The target pricing ranges from a high JNJ forecast of $195 down to a low forecast of $163. Johnson & Johnson (JNJ)’s last closing stock price was $151.24 which would put the average price target at 18.69% upside.
In addition, TradingView issued a rating for JNJ stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a n/a short-term outlook. Remember, securities are volatile, so please do your own research on JNJ stock.
Other analysts covering JNJ include:
- Larry Biegelsen of Wells Fargo issued a Hold rating with the price target of $163 on 1 day ago
- Joanne Wuensch of Citi issued a Buy rating with the price target of $185 on 2 days ago
- Shagun Singh Chadha of RBC Capital issued a Buy rating with the price target of $175 on 5 days ago
- David Risinger of Leerink Partners issued a Buy rating with the price target of n/a on 2 weeks ago
If you are wondering if JNJ is a good stock to buy, here are 3rd party ratings for JNJ stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: n/a Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 24% (189 out of 248)
What is the sentiment on the street regarding Johnson & Johnson? (Current ratings compiled by TipRanks.com)
- News Sentiment for JNJ stock: Bullish
- Blogger Consensus for JNJ stock: {Blogger Consensus}
- Media Buzz for JNJ stock: Strong Buy
- Insider Signal for JNJ stock: Selling
- Investor Sentiment for JNJ stock: Negative
- Hedge Fund signal for JNJ stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on JNJ stock including scouring the social networks like JNJ StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for JNJ stock chart >>
Summary: Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.
- Recent JSPR Stock Price: $23.10
- Yearly Gain for JSPR stock: 29.05%
- Market Cap for JSPR stock: $348.48M
- P/E Ratio for JSPR stock: -0.37
Will JSPR's stock price go up? Is there an accurate JSPR stock forecast available?
TipRanks.com reports that Jasper Therapeutics, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $63.75. The target pricing ranges from a high JSPR forecast of $70 down to a low forecast of $55. Jasper Therapeutics, Inc. (JSPR)’s last closing stock price was $23.10 which would put the average price target at 175.97% upside.
In addition, TradingView issued a rating for JSPR stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a n/a short-term outlook. Remember, securities are volatile, so please do your own research on JSPR stock.
Other analysts covering JSPR include:
- Emily Bodnar of H.C. Wainwright issued a Buy rating with the price target of $65 on 1 day ago
- Tim Chiang of Capital One Financial issued a Buy rating with the price target of $55 on 1 day ago
- Gregory Renza of RBC Capital issued a Buy rating with the price target of $70 on 1 week ago
- Gavin Clark-Gartner of Evercore ISI issued a Buy rating with the price target of $65 on 1 month ago
If you are wondering if JSPR is a good stock to buy, here are 3rd party ratings for JSPR stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: n/a Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 35% (88 out of 248)
What is the sentiment on the street regarding Jasper Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for JSPR stock: Bullish
- Blogger Consensus for JSPR stock: {Blogger Consensus}
- Media Buzz for JSPR stock: Neutral
- Insider Signal for JSPR stock: Buying
- Investor Sentiment for JSPR stock: Positive
- Hedge Fund signal for JSPR stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on JSPR stock including scouring the social networks like JSPR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for JSPR stock chart >>
Summary: Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.
- Recent LRMR Stock Price: $7.89
- Yearly Gain for LRMR stock: 117.36%
- Market Cap for LRMR stock: $503.38M
- P/E Ratio for LRMR stock: -8.22
Will LRMR's stock price go up? Is there an accurate LRMR stock forecast available?
TipRanks.com reports that Larimar Therapeutics, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $21.75. The target pricing ranges from a high LRMR forecast of $27 down to a low forecast of $10. Larimar Therapeutics, Inc. (LRMR)’s last closing stock price was $7.89 which would put the average price target at 175.67% upside.
In addition, TradingView issued a rating for LRMR stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a n/a short-term outlook. Remember, securities are volatile, so please do your own research on LRMR stock.
Other analysts covering LRMR include:
- Cory Jubinville, PhD of LifeSci Capital issued a Buy rating with the price target of $27 on 1 day ago
- Joseph Schwartz of Leerink Partners issued a Buy rating with the price target of n/a on 1 day ago
- Samantha Semenkow of Citi issued a Buy rating with the price target of $10 on 3 months ago
- Yatin Suneja of Guggenheim issued a Buy rating with the price target of $25 on 3 months ago
If you are wondering if LRMR is a good stock to buy, here are 3rd party ratings for LRMR stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: n/a Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Sell, Top 36% (90 out of 248)
What is the sentiment on the street regarding Larimar Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for LRMR stock: Bearish
- Blogger Consensus for LRMR stock: {Blogger Consensus}
- Media Buzz for LRMR stock: Sell
- Insider Signal for LRMR stock: Selling
- Investor Sentiment for LRMR stock: Positive
- Hedge Fund signal for LRMR stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on LRMR stock including scouring the social networks like LRMR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for LRMR stock chart >>
Summary: Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.
- Recent DYN Stock Price: $32.63
- Yearly Gain for DYN stock: 134.24%
- Market Cap for DYN stock: $2.65B
- P/E Ratio for DYN stock: -8.2
Will DYN's stock price go up? Is there an accurate DYN stock forecast available?
TipRanks.com reports that Dyne Therapeutics, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $45.75. The target pricing ranges from a high DYN forecast of $48 down to a low forecast of $42. Dyne Therapeutics, Inc. (DYN)’s last closing stock price was $32.63 which would put the average price target at 40.21% upside.
In addition, TradingView issued a rating for DYN stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a n/a short-term outlook. Remember, securities are volatile, so please do your own research on DYN stock.
Other analysts covering DYN include:
- Debjit Chattopadhyay of Guggenheim issued a Buy rating with the price target of $45 on 1 day ago
- Andrew Fein of H.C. Wainwright issued a Buy rating with the price target of $48 on 1 day ago
- Tessa Romero of J.P. Morgan issued a Buy rating with the price target of n/a on 1 day ago
- Michael Ulz of Morgan Stanley issued a Buy rating with the price target of $48 on 1 day ago
If you are wondering if DYN is a good stock to buy, here are 3rd party ratings for DYN stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: n/a Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 36% (90 out of 248)
What is the sentiment on the street regarding Dyne Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for DYN stock: Bearish
- Blogger Consensus for DYN stock: {Blogger Consensus}
- Media Buzz for DYN stock: Neutral
- Insider Signal for DYN stock: Selling
- Investor Sentiment for DYN stock: Positive
- Hedge Fund signal for DYN stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on DYN stock including scouring the social networks like DYN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for DYN stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
